Apolipoprotein-mimetic nanodiscs reduce lipid accumulation and improve liver function in acid sphingomyelinase deficiency.

[1]  Shen Jin,et al.  Physiological functions and therapeutic applications of neutral sphingomyelinase and acid sphingomyelinase. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  L. Deckelbaum,et al.  Rationale and design of ApoA-I event reducing in ischemic syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. , 2020, American heart journal.

[3]  H. Paulson,et al.  Synthetic high-density lipoprotein nanoparticles for the treatment of Niemann–Pick diseases , 2019, BMC Medicine.

[4]  A. Schwendeman,et al.  Characterization of apolipoprotein A-I peptide phospholipid interaction and its effect on HDL nanodisc assembly , 2019, International journal of nanomedicine.

[5]  J. Kastelein,et al.  Effect of Serial Infusions of CER-001, a Pre-&bgr; High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial , 2018, JAMA cardiology.

[6]  Jie Tang,et al.  Influence of route of administration and lipidation of apolipoprotein A-I peptide on pharmacokinetics and cholesterol mobilization[S] , 2016, Journal of Lipid Research.

[7]  Y. E. Chen,et al.  High-Density Lipoproteins: Nature's Multifunctional Nanoparticles. , 2016, ACS nano.

[8]  E. Schuchman,et al.  Types A and B Niemann-Pick disease. , 2015, Best practice & research. Clinical endocrinology & metabolism.

[9]  M. Pfeffer,et al.  Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial , 2014, European heart journal.

[10]  P. Barter,et al.  The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins. , 2011, Atherosclerosis.

[11]  D. Sviridov,et al.  5A Apolipoprotein Mimetic Peptide Promotes Cholesterol Efflux and Reduces Atherosclerosis in Mice , 2010, Journal of Pharmacology and Experimental Therapeutics.

[12]  R. Duan.  Alkaline sphingomyelinase: an old enzyme with novel implications. , 2006, Biochimica et biophysica acta.

[13]  A. Lesimple,et al.  Increased sphingomyelin content impairs HDL biogenesis and maturation in human Niemann-Pick disease type B Published, JLR Papers in Press, November 30, 2005. , 2006, Journal of Lipid Research.

[14]  S. Hossain,et al.  The Natural History of Type B Niemann-Pick Disease: Results From a 10-Year Longitudinal Study , 2004, Pediatrics.

[15]  R. Desnick,et al.  Lipid abnormalities in children with types A and B Niemann Pick disease. , 2004, The Journal of pediatrics.

[16]  Paul Schoenhagen,et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[17]  C. Devlin,et al.  Creation of a mouse model for non-neurological (type B) Niemann-Pick disease by stable, low level expression of lysosomal sphingomyelinase in the absence of secretory sphingomyelinase: relationship between brain intra-lysosomal enzyme activity and central nervous system function. , 2000, Human molecular genetics.

[18]  R. Hovorka,et al.  Effects of intravenous infusion of lipid-free apo A-I in humans. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[19]  D. Perl,et al.  Acid sphingomyelinase deficient mice: a model of types A and B Niemann–Pick disease , 1995, Nature Genetics.

[20]  E. P. Kennedy,et al.  Sphingomyelinase in normal human spleens and in spleens from subjects with Niemann-Pick disease. , 1967, Journal of lipid research.

[21]  R. Brady,et al.  The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick diseae. , 1966, Proceedings of the National Academy of Sciences of the United States of America.

[22]  H. Gupta,et al.  Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH(2). , 2010, Atherosclerosis.

[23]  Minghan Wang,et al.  HDL: the metabolism, function, and therapeutic importance. , 2004, Chemical reviews.